CHICAGO — First-line chemotherapy plus bevacizumab and durvalumab — followed by maintenance durvalumab, bevacizumab and olaparib — extended PFS compared with standard of care for women with non-BRCA-mutated advanced ovarian cancer.The findings of an interim analysis of the three-arm, randomized phase 3 DUO-O trial, presented at ASCO Annual Meeting, also noted a numerical
Norman Merrill II, 46, pleaded guilty in December to one count of possession of child sexual abuse materials, according to court documents. Two remaining counts were dismissed.
The FDA expanded the approval of abemaciclib, combined with endocrine therapy, as adjuvant treatment for adults with hormone receptor-positive, HER2-negative, node-positive early breast cancer.
The label expansion removes the Ki-67 score requirement for selection of patients for treatment with abemaciclib (Verzenio, Eli Lilly), a cyclin-dependent kinase (CDK) 4/6 inhibitor. Patients with